We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2024-02-14 Interview with Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy

Watch the interview in Swedish here

2024-01-24 Redeye Fight Cancer Event 2024

CEO Göran Forsberg presents at Redeye Fight Cancer Event 2024

Watch the presentation here

2023-10-03 Redeye Autoimmune & Inflammatory Disease Event

David Liberg, CSO Cantargia, presents at Redeye Autoimmune & Inflammatory Disease Event

Watch the presentation here


Current corporate presentation

Download the corporate presentation as PDF